Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial

PURPOSE: The ACOSOG (American College of Surgeons Oncology Group) Z9001 (Alliance) study, a randomized, placebo-controlled trial, demonstrated that 1 year of adjuvant imatinib prolonged recurrence-free survival (RFS) after resection of primary GI stromal tumor (GIST). We sought to determine the path...

Full description

Saved in:
Bibliographic Details
Main Authors: Corless, Christopher L., Ballman, Karla V., Antonescu, Cristina R., Kolesnikova, Violetta, Maki, Robert G., Pisters, Peter W.T., Blackstein, Martin E., Blanke, Charles D., Demetri, George D., Heinrich, Michael C., von Mehren, Margaret, Patel, Shreyaskumar, McCarter, Martin D., Owzar, Kouros, DeMatteo, Ronald P.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2014
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4026579/
https://ncbi.nlm.nih.gov/pubmed/24638003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.2046
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items